STOCK TITAN

Arch Biopartners Inc. - ACHFF STOCK NEWS

Welcome to our dedicated news page for Arch Biopartners (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on Arch Biopartners.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arch Biopartners's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arch Biopartners's position in the market.

Rhea-AI Summary
Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) has submitted a Clinical Trial Application to Health Canada for a Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial plans to recruit up to 240 patients in Canada, Turkey, and the United States, with patient recruitment expected to begin in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary
Arch Biopartners Inc. submits applications for Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI) in Turkey. Phase II trial plans to recruit up to 240 patients and will be conducted in the U.S., Turkey, and Canada. Patient recruitment expected to begin in Q4 2023. LSALT peptide has shown promise in preventing ischemia reperfusion injury (IRI) to the kidneys. Funding contribution from NRC-IRAP will offset trial costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
none
Arch Biopartners Inc.

OTC:ACHFF

ACHFF Rankings

ACHFF Stock Data

108.11M
49.02M
19.01%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
Canada
Toronto